Leukemic transformation

Cancer Biology and Therapy

Volumn 3, Issue 1, 2004, Pages 13-20

  Lin, Ying Wei ^a,b   Aplan, Peter D ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b KYOTO UNIVERSITY   (Japan)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Differentiation; Disrupted differentiation; Enhanced proliferation; Genomic instability; Leukemia; Leukemic transformation; Molecular target; Mutation; Proliferation

Indexed keywords

IMATINIB;

BLOOD CELL; CANCER GENETICS; CELL DIFFERENTIATION; CHROMOSOME REARRANGEMENT; CHROMOSOME SUBSTITUTION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; EPIGENETICS; GENE AMPLIFICATION; GENE DELETION; GENE INSERTION; GENE MUTATION; GENE TARGETING; GENE THERAPY; GENE TRANSLOCATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HUMAN; LEUKEMIA; NONHUMAN; PATHOGENESIS; POINT MUTATION; PROTEIN FUNCTION; REVIEW; CELL TRANSFORMATION; CHROMOSOME MAP; GENETICS; KARYOTYPING; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY;

CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME MAPPING; HUMANS; KARYOTYPING; LEUKEMIA; MUTATION;

EID: 3142518219     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.1.537     Document Type: Review

References (109)

1. Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003; 95:1276-99.
2. Gilliland DG. Molecular genetics of human leukemias: New insights into therapy. Semin Hematol 2002; 39:6-11.
3. Birkenmeier EH, Gwynn B, Howard S, Jerry J, Gordon JI, Landschulz WH, et al. Tissue-specific expression, developmental regulation, and genetic mapping of the gene encoding CCAAT/enhancer binding protein. Genes Dev 1989; 3:1146-56.
4. Scott LM, Civin CI, Rorth P , Friedman AD. A novel temporal expression pattern of three C/EBP family members in differentiating myelomonocytic cells. Blood 1992; 80:1725-35.
5. Chandrasekaran C , Gordon JI. Cell lineage-specific and differentiation-dependent patterns of CCAAT/enhancer binding protein alpha expression in the gut epithelium of normal and transgenic mice. Proc Natl Acad Sci USA 1993; 90:8871-5.
6. Antonson P , Xanthopoulos KG. Molecular cloning, sequence, and expression patterns of the human gene encoding CCAAT/enhancer binding protein alpha (C/EBP alpha). Biochem Biophys Res Commun 1995; 215:106-13.
7. Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ , Tenen DG. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci USA 1997; 94:569-74.
8. Hohaus S, Petrovick MS, Voso MT, Sun Z, Zhang DE , Tenen DG. PU.1 (Spi-1) and C/EBP alpha regulate expression of the granulocyte-macrophage colony-stimulating factor receptor alpha gene. Mol Cell Biol 1995; 15:5830-45.
9. Smith LT, Hohaus S, Gonzalez DA, Dziennis SE , Tenen DG. PU.1 (Spi-1) and C/EBP alpha regulate the granulocyte colony-stimulating factor receptor promoter in myeloid cells. Blood 1996; 88:1234-47.
10. Radomska HS, Huettner CS, Zhang P, Cheng T, Scadden DT , Tenen DG. CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol 1998; 18:4301-14.
11. Timchenko NA, Harris TE, Wilde M, Bilyeu TA, Burgess-Beusse BL, Finegold MJ, et al. CCAAT/enhancer binding protein alpha regulates p21 protein and hepatocyte proliferation in newborn mice. Mol Cell Biol 1997; 17:7353-61.
12. Harris TE, Albrecht JH, Nakanishi M, Darlington GJ. CCAAT/enhancer- binding protein-alpha cooperates with p21 to inhibit cyclin-dependent kinase-2 activity and induces growth arrest independent of DNA binding. J Biol Chem 2001; 276:29200-9.
13. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001; 27:263-70.
14. Gombart AF, Hofmann WK, Kawano S, Takeuchi S, Krug U, Kwok SH, et al. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood 2002; 99:1332-40.
15. Shimizu K, Kitabayashi I, Kamada N, Abe T, Maseki N, Suzukawa K, et al. AML1-MTG8 leukemic protein induces the expression of granulocyte colony-stimulating factor (G-CSF) receptor through the up-regulation of CCAAT/enhancer binding protein epsilon. Blood 2000; 96:288-96.
16. Cao W, Britos-Bray M, Claxton DF, Kelley CA, Speck NA, Liu PP, et al. CBF beta-SMMHC, expressed in M4Eo AML, reduced CBF DNA-binding and inhibited the G1 to S cell cycle transition at the restriction point in myeloid and lymphoid cells. Oncogene 1997; 15:1315-27.
17. Halle JP, Haus-Seuffert P, Woltering C, Stelzer G , Meisterernst M. A conserved tissue-specific structure at a human T-cell receptor beta-chain core promoter. Mol Cell Biol 1997; 17:4220-9.
18. Austin GE, Zhao WG, Regmi A, Lu JP, Braun J. Identification of an upstream enhancer containing an AML1 site in the human myeloperoxidase (MPO) gene. Leuk Res 1998; 22:1037-48.
19. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996; 84:321-30.
20. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci USA 1996; 93:3444-9.
21. Taketani T, Taki T, Takita J, Tsuchida M, Hanada R, Hongo T, et al. AML1/RUNX1 mutations are infrequent, but related to AML-M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignancies. Genes Chromosomes Cancer 2003; 38:1-7.
22. Osato M, Asou N, Abdalla E, Hoshino K, Yamasaki H, Okubo T, et al. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. Blood 1999; 93:1817-24.
23. Imai Y, Kurokawa M, Izutsu K, Hangaishi A, Takeuchi K, Maki K, et al. Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. Blood 2000; 96:3154-00.
24. Preudhomme C, Warot-Loze D, Roumier C, Grardel-Duflos N, Garand R, Lai JL, et al. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood 2000; 96:2862-9.
25. Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, Le Beau MM, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002; 32:148-52.
26. Rainis L, Bercovich D, Strehl S, Teigler-Schlegel A, Stark B, Trka J, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood 2003; 102:981-6.
27. Taylor JA, Sandler DP, Bloomfield CD, Shore DL, Ball ED, Neubauer A, et al. ras oncogene activation and occupational exposures in acute myeloid leukemia. J Natl Cancer Inst 1992; 84:1626-32.
28. Graham SV, Tindle RW, Birnie GD. Variation in myc gene amplification and expression in sublines of HL60 cells. Leuk Res 1985; 9:239-47.
29. Ariyama Y, Fukuda Y, Okuno Y, Seto M, Date K, Abe T, et al. Amplification on double-minute chromosomes and partial-tandem duplication of the MLL gene in leukemic cells of a patient with acute myelogenous leukemia. Genes Chromosomes Cancer 1998; 23:267-72.
30. Kojima S, Matsuyama T, Sato T, Horibe K, Konishi S, Tsuchida M, et al. Down's syndrome and acute leukemia in children: An analysis of phenotype by use of monoclonal antibodies and electron microscopic platelet peroxidase reaction. Blood 1990; 76:2348-53.
31. Paulsson K, Fioretos T, Strombeck B, Mauritzson N, Tanke HJ, Johansson B. Trisomy 8 as the sole chromosomal aberration in myelocytic malignancies: A multicolor and locus-specific fluorescence in situ hybridization study. Cancer Genet Cytogenet 2003; 140:66-9.
32. Swolin B, Weinfeld A, Ridell B, Waldenstrom J, Westin J. On the 5q- deletion: Clinical and cytogenetic observations in ten patients and review of the literature. Blood 1981; 58:986-93.
33. Pedersen B, Kerndrup G. Specific minor chromosome deletions consistently occurring in myelodysplastic syndromes. Cancer Genet Cytogenet 1986; 23:61-75.
34. Hayette S, Thomas X, Bertrand Y, Tigaud I, Callanan M, Thiebaut A, et al. Molecular analysis of cyclin-dependent kinase inhibitors in human leukemias. Leukemia 1997; 11:1696-9.
35. Murphree AL, Benedict WF. Retinoblastoma: Clues to human oncogenesis. Science 1984; 223:1028-33.
36. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83:993-1000.
37. Batova A, Diccianni MB, Yu JC, Nobori T, Link MP, Pullen J, et al. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res 1997; 57:832-6.
38. Solomon E, Borrow J, Goddard AD. Chromosome aberrations and cancer. Science 1991; 254:1153-60.
39. Raimondi SC. Current status of cytogenetic research in childhood acute lymphoblastic leukemia. Blood 1993; 81:2237-51.
40. Ahn MY, Huang G, Bae SC, Wee HJ, Kim WY, Ito Y. Negative regulation of granulocytic differentiation in the myeloid precursor cell line 32Dcl3 by ear-2, a mammalian homolog of Drosophila seven-up, and a chimeric leukemogenic gene, AML1/ETO. Proc Natl Acad Sci USA 1998; 95:1812-7.
41. Rhoades KL, Hetherington CJ, Rowley JD, Hiebert SW, Nucifora G, Tenen DG, et al. Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis. Proc Natl Acad Sci USA 1996; 93:11895-900.
42. Peltomaki P, Vasen HF. Mutations predisposing to hereditary nonpolyposis colorectal cancer: Database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 1997; 113:1146-58.
43. Kolodner RD, Tytell JD, Schmeits JL, Kane MF, Gupta RD, Weger J, et al. Germ-line msh6 mutations in colorectal cancer families. Cancer Res 1999; 59:5068-74.
44. Eshleman JR, Lang EZ, Bowerfind GK, Parsons R, Vogelstein B, Willson JK, et al. Increased mutation rate at the hprt locus acc
45. Wahlberg SS, Schmeits J, Thomas G, Loda M, Garber J, Syngal S, et al. Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res 2002; 62:3485-92.
46. Edelmann W, Yang K, Umar A, Heyer J, Lau K, Fan K, et al. Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. Cell 1997; 91:467-77.
47. Lowsky R, DeCoteau JF, Reitmair AH, Ichinohasama R, Dong WF, Xu Y, et al. Defects of the mismatch repair gene MSH2 are implicated in the development of murine and human lymphoblastic lymphomas and are associated with the aberrant expression of rhombotin-2 (Lmo-2) and Tal-1 (SCL). Blood 1997; 89:2276-82.
48. Zhu YM, Das-Gupta EP , Russell NH. Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. Blood 1999; 94:733-40.
49. Lin YW, Perkins JJ, Zhang Z, Aplan PD. Distinct Mechanisms Lead To HPRT Gene Mutations In Leukemic Cells. Genes Chromosomes Cancer; In press.
50. Rotman G , Shiloh Y. ATM: from gene to function. Hum Mol Genet 1998; 7:1555-63.
51. Horwitz M. The genetics of familial leukemia. Leukemia 1997; 11:1347-59.
52. Roth DB , Craig NL. VDJ recombination: a transposase goes to work. Cell 1998; 94:411-4.
53. Grawunder U, West RB , Lieber MR. Antigen receptor gene rearrangement. Curr Opin Immunol 1998; 10:172-80
54. Jeffs AR, Benjes SM, Smith TL, Sowerby SJ , Morris CM. The BCR gene recombines preferentially with Alu elements in complex BCR-ABL translocations of chronic myeloid leukaemia. Hum Mol Genet 1998; 7:767-76.
55. Zhang JG, Goldman JM , Cross NC. Characterization of genomic BCR-ABL breakpoints in chronic myeloid leukaemia by PCR. Br J Haematol 1995; 90:138-46.
56. Strout MP, Marcucci G, Bloomfield CD , Caligiuri MA. The partial tandem duplication of ALL1 (MLL) is consistently generated by Alu-mediated homologous recombination in acute myeloid leukemia. Proc Natl Acad Sci USA 1998; 95:2390-5.
57. Thandla SP, Ploski JE, Raza-Egilmez SZ, Chhalliyil PP, Block AW, de Jong PJ, et al. ETV6-AML1 translocation breakpoints cluster near a purine/pyrimidine repeat region in the ETV6 gene. Blood 1999; 93:293-9.
58. Aplan PD, Raimondi SC , Kirsch IR. Disruption of the SCL gene by a t(1;3) translocation in a patient with T cell acute lymphoblastic leukemia. J Exp Med 1992; 176:1303-10.
59. Boehm T, Mengle-Gaw L, Kees UR, Spurr N, Lavenir I, Forster A, et al. Alternating purine-pyrimidine tracts may promote chromosomal translocations seen in a variety of human lymphoid tumours. EMBO J 1989; 8:2621-31.
60. Dutreix M. (GT)n repetitive tracts affect several stages of RecA-promoted recombination. J Mol Biol 1997; 273:105-13.
61. Samadashwily GM, Raca G , Mirkin SM. Trinucleotide repeats affect DNA replication in vivo. Nat Genet 1997; 17:298-304.
62. Smith MA, McCaffrey RP , Karp JE. The secondary leukemias: challenges and research directions. J Natl Cancer Inst 1996; 88:407-18.
63. Pedersen-Bjergaard J, Pedersen M, Roulston D , Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995; 86:3542-52.
64. Smith MA, Rubinstein L , Ungerleider RS. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med Pediatr Oncol 1994; 23:86-98.
65. Aplan PD, Chervinsky DS, Stanulla M , Burhans WC. Site-specific DNA cleavage within the MLL breakpoint cluster region induced by topoisomerase II inhibitors. Blood 1996; 87:2649-58.
66. Maraschin J, Dutrillaux B , Aurias A. Chromosome aberrations induced by etoposide (VP-16) are not random. Int J Cancer 1990; 46:808-12.
67. Ahuja HG, Felk CA , Aplan PD. Potential role for DNA topoisomerase II poisons in the generation of t(11;20)(p15;q11) translocations. Genes Chromosomes Cancer 2000; 29:96-105.
68. Lovett BD, Lo Nigro L, Rappaport EF, Blair IA, Osheroff N, Zheng N, et al. Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation. Proc Natl Acad Sci USA 2001; 98:9802-7.
69. Stanulla M, Wang J, Chervinsky DS, Thandla S , Aplan PD. DNA cleavage within the MLL breakpoint cluster region is a specific event which occurs as part of higher-order chromatin fragmentation during the initial stages of apoptosis. Mol Cell Biol 1997; 17:4070-9.
70. Reichel M, Gillert E, Nilson I, Siegler G, Greil J, Fey GH, et al. Fine structure of translocation breakpoints in leukemic blasts with chromosomal translocation t(4;11): the DNA damage-repair model of translocation. Oncogene 1998; 17:3035-44.
71. Strissel PL, Strick R, Tomek RJ, Roe BA, Rowley JD , Zeleznik-Le NJ. DNA structural properties of AF9 are similar to MLL and could act as recombination hot spots resulting in MLL/AF9 translocations and leukemogenesis. Hum Mol Genet 2000; 9:1671-9.
72. Betti CJ, Villalobos MJ, Diaz MO , Vaughan AT. Apoptotic stimuli initiate MLL-AF9 translocations that are transcribed in cells capable of division. Cancer Res 2003; 63:1377-81.
73. Langer T, Metzler M, Reinhardt D, Viehmann S, Borkhardt A, Reichel M, et al. Analysis of t(9;11) chromosomal breakpoint sequences in childhood acute leukemia: almost identical MLL breakpoints in therapy-related AML after treatment without etoposides. Genes Chromosomes Cancer 2003; 36:393-401.
74. Weiss A , Littman DR. Signal transduction by lymphocyte antigen receptors. Cell 1994; 76:263-74.
75. Straus DB , Weiss A. The CD3 chains of the T cell antigen receptor associate with the ZAP-70 tyrosine kinase and are tyrosine phosphorylated after receptor stimulation. J Exp Med 1993; 178:1523-30.
76. Berridge MJ. Inositol trisphosphate and diacylglycerol: two interacting second messengers. Annu Rev Biochem 1987; 56:159-93.
77. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 1988; 334:661-5.
78. Davis RJ. MAPKs: new JNK expands the group. Trends Biochem Sci 1994; 19:470-3.
79. Kyriakis JM , Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001; 81:807-69.
80. Amakawa R, Fukuhara S, Ohno H, Matsuyama F, Kato I, Tanabe S, et al. Genomic organization of IgH gene compared with the expression of Bcl-2 gene in t(14;18)-positive lymphoma. Blood 1991; 77:1970-6.
81. Jager U, Bocskor S, Le T, Mitterbauer G, Bolz I, Chott A, et al. Follicular lymphomas' BCL-2/IgH junctions contain templated nucleotide insertions: novel insights into the mechanism of t(14;18) translocation. Blood 2000; 95:3520-9.
82. Makover D, Cuddy M, Yum S, Bradley K, Alpers J, Sukhatme V, et al. Phorbol ester-mediated inhibition of growth and regulation of proto-oncogene expression in the human T cell leukemia line JURKAT. Oncogene 1991; 6:455-60.
83. Meijerink JP, Mensink EJ, Wang K, Sedlak TW, Sloetjes AW, de Witte T, et al. Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood 1998; 91:2991-7.
84. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998; 391:815-8.
85. Perez A, Kastner P, Sethi S, Lutz Y, Reibel C , Chambon P. PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR. EMBO J 1993; 12:3171-82.
86. Lin RJ , Evans RM. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell 2000; 5:821-30.
87. Minucci S, Maccarana M, Cioce M, De Luca P, Gelmetti V, Segalla S, et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell 2000; 5:811-20.
88. Sohal J, Phan VT, Chan PV, Davis EM, Patel B, Kelly LM, et al. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood 2003; 101:3188-97.
89. Dash AB, Williams IR, Kutok JL, Tomasson MH, Anastasiadou E, Lindahl K, et al. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc Natl Acad Sci USA 2002; 99:7622-7.
90. Robb L, Lyons I, Li R, Hartley L, Kontgen F, Harvey RP, et al. Absence of yolk sac hematopoiesis from mice with a targeted disruption of the scl gene. Proc Natl Acad Sci USA 1995; 92:7075-9.
91. Porcher C, Swat W, Rockwell K, Fujiwara Y, Alt FW , Orkin SH. The T cell leukemia oncoprotein SCL/tal-1 is essential for development of all hematopoietic lineages. Cell 1996; 86:47-57.
92. Herblot S, Steff AM, Hugo P, Aplan PD , Hoang T. SCL and LMO1 alter thymocyte differentiation: inhibition of E2A-HEB function and pre-T alpha chain expression. Nat Immunol 2000; 1:138-44.
93. Aplan PD, Jones CA, Chervinsky DS, Zhao X, Ellsworth M, Wu C, et al. An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T-cell malignancies in transgenic mice. EMBO J 1997; 16:2408-19
94. Petkovich M, Brand NJ, Krust A , Chambon P. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 1987; 330:444-50.
95. Giguere V, Ong ES, Segui P , Evans RM. Identification of a receptor for the morphogen retinoic acid. Nature 1987; 330:624-9.
96. Warrell RP, Jr., de The H, Wang ZY , Degos L. Acute promyelocytic leukemia. N Engl J Med 1993; 329:177-89.
97. Liu TX, Zhang JW, Tao J, Zhang RB, Zhang QH, Zhao CJ, et al. Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells. Blood 2000; 96:1496-504.
98. Chen JD , Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 1995; 377:454-7
99. Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 1995; 377:397-404.
100. Lin RJ, Sternsdorf T, Tini M , Evans RM. Transcriptional regulation in acute promyelocytic leukemia. Oncogene 2001; 20:7204-15.
101. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2:561-6.
102. Gambacorti-Passerini C, le Coutre P, Mologni L, Fanelli M, Bertazzoli C, Marchesi E, et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997; 23:380-94.
103. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346:645-52.
104. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344:1038-42.
105. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996; 14:18-24.
106. Pui CH, Campana D , Evans WE. Childhood acute lymphoblastic leukaemia - current status and future perspectives. Lancet Oncol 2001; 2:597-607.
107. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288:669-72.
108. Kohn DB, Sadelain M , Glorioso JC. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 2003; 3:477-88.
109. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302:415-9.